Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;21(12):1630-1631.
doi: 10.1016/S1473-3099(21)00695-2.

Assessing the evidence on remdesivir

Marius Trøseid  1 , Maya Hites  2 , Andreas Barratt-Due  3 , Florence Ader  4 , Yazdan Yazdanpanah  5
Affiliations

Assessing the evidence on remdesivir

Marius Trøseid et al. Lancet Infect Dis. 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

This work is a collaboration within the EU-RESPONSE project, which has received funding from the EU Horizon 2020 Research and Innovation programme, under the grant number 101015736. MT has participated without pay in Eli Lilly's European advisory board. MH has received funding for the DisCoVeRy and COV-AID trials from the Federal Belgian Center for Knowledge and the joint Université Libre de Bruxelles-Fonds Erasme-COVID-19 projects. MH has also participated in Gilead's educational advisory board on invasive aspergillosis infections, is an editor of the Belgian Framingham's Journal on Infectious Diseases, and received support from Pfizer to attend the ECCMID 2021 congress. All other authors declare no competing interests.

Comment in

  • Assessing the evidence on remdesivir.
    Núñez I, Soto-Mota A. Núñez I, et al. Lancet Infect Dis. 2021 Dec;21(12):1630. doi: 10.1016/S1473-3099(21)00693-9. Lancet Infect Dis. 2021. PMID: 34838223 Free PMC article. No abstract available.

Similar articles

See all similar articles

Cited by

References

    1. Gyselinck I, Janssens W. Remdesivir, on the road to DisCoVeRy. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00559-4. published online Sept 14. - DOI - PMC - PubMed
    1. Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00485-0. published online Sept 14. - DOI - PMC - PubMed
    1. Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;20:656–657. - PMC - PubMed
    1. Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, et al. Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: a randomized trial. Ann Intern Med. 2021;174:1261–1269. - PMC - PubMed
    1. Hill JA, Paredes Deiros R, Vaca C, et al. IDWeek; 2021. Remdesivir for the treatment of high-risk non-hospitalized individuals with COVID-19: a randomized, double-blind, placebo-controlled trial. online; Sept 29 to Oct 3, 2021 (oral LB1).

Uncited Reference

    1. Horby PW, Mafham M, Peto L, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021 doi: 10.1101/2021.06.15.21258542. published online June 16. (preprint) - DOI - PMC - PubMed

MeSH terms